GlassScriptPhysician profile
Carter J Boyd
NPI 1982713483
$5,630.89
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,486 · 2020: $1,444 · 2021: $1,501 · 2022: $667 · 2023: $433 · 2024: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,071.01 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $798.01 | 2019-2021 | |
| Horizon Therapeutics Plc | $612.12 | 2019-2021 | |
| Abbvie INC. | $514.89 | 2021-2022 | |
| Allergan, INC. | $489.26 | 2019-2020 | |
| Shire North American Group INC | $411.08 | 2019 | |
| Lilly USA, LLC | $316.75 | 2019-2023 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.19 | 2019-2020 | |
| Axogen | $211.69 | 2020 | |
| Kerecis Limited | $147.46 | 2021 | |
| Sientra, INC. | $143.13 | 2022 | |
| Acell, INC. | $140.88 | 2020 | |
| Acumed LLC | $100.04 | 2024 | Inframe Implant, Innate Implant |
| Hikma Pharmaceuticals USA | $84.84 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $72.21 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $37.32 | 2023 | Jornay Pm |
| Evoke Pharma, INC. | $37.27 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.34 | 2021 | |
| Eyevance Pharmaceuticals LLC | $23.66 | 2021 | |
| Halozyme INC | $22.35 | 2023 | |
| Mylan Specialty L.P. | $22.00 | 2021 | |
| Zyla Life Sciences, INC. | $19.42 | 2020 | |
| Amgen INC. | $18.36 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.78 | 2023 | Breztri |
| Medtronic, INC. | $16.60 | 2021 | |
| Astellas Pharma US INC | $15.00 | 2023 | Veozah |
| Avion Pharmaceuticals | $13.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carter Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.